Susan Almon-Pesch Named One of San Diego’s Top Marketing Executives 2022 by SD METRO Magazine

Susan Almon-Pesch Named One of San Diego’s Top Marketing Executives 2022 by SD METRO Magazine

Post Views: 240 SD METRO Magazine recognized Susan Almon-Pesch along with ten other talented PR and marketing executives in its January 2022 cover story featuring San Diego’s top professionals in the industry. Honoree, Almon-Pesch, is the owner of Market 4 Profit. Founded in San Diego, California in 1999, the marketing and public relations agency serves…

IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE™ Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform

IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE™ Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform

Post Views: 207 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported the acquisition of its INQUIRE™ Chemical Library to enhance the company’s synthetic lethality drug discovery platform. IDEAYA’s INQUIRE Chemical Library is a proprietary, expert-curated small-molecule library of over 200,000 chemical…

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

Post Views: 169 Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that its subsidiary, Oravax Medical, has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company to pre-purchase Oravax’s oral COVID-19 vaccine, currently in…

American Gene Technologies’ HIV Clinical Trial Generates Promising Efficacy Data Markers

Post Views: 262 American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, announced that it has reached two important milestones for its HIV cure program. All three patients achieved engraftment of the genetically modified cell product, AGT103-T, and avoided rejection of the infused cells. In addition, patient samples were challenged to determine…